ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

707
Analysis
Health Care • China
Wuxi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development, and manufacturing, including complex modalities like monoclonal antibodies and antibody-drug conjugates. The company provides comprehensive services from concept to commercialization, including vaccine CRDMO services. It was founded in 2010 and is headquartered in Wuxi, China.
more
•27 Nov 2020 04:36

China's Next Generation:  Diversifying Away from Tencent and Alibaba.

China exposure is becoming more concentrated in a small number of large cap stocks.  We identify the next generation of China stocks by analyzing...

Logo
531 Views
Share
•29 Jun 2026 14:00

HSI Index Earning Revision (Jun): TENCENT, AIA, PETROCHINA, LONGFOR, TRIP.COM, MEITUAN

We analyzed HSI's consensus for Jun 2026 and highlighted changes of EPS in TENCENT, AIA, PETROCHINA, LONGFOR, TRIP.COM, MEITUAN.

Logo
197 Views
Share
•26 Jun 2026 10:11

Hong Kong Buybacks Weekly (Jun 26th): Tencent, Xiaomi, Guming, Meitu

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
136 Views
Share
•29 Jun 2020 23:52

Global Equity Chart Book: Stick With EM Over EAFE

With RS uptrends intact we continue to recommend Sector overweights to MSCI EM Technology, Consumer Discretionary, Health Care, and Communications....

Logo
643 Views
Share
bullish•Pop Mart
•22 Jun 2026 04:42

Pop Mart, Trip.com, Geely Auto, and More: Weekly Options Start Trading on 15 June

Today, HKEX launches weekly trading in options on Geely (175 HK), Li Auto (2015 HK), XPeng (9868 HK), NetEase (9999 HK), Sun Hung Kai Properties...

Logo
156 Views
Share
x